Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Plos One|September 28, 2011
11β-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repairMika Terao, Hiroyuki Murota, Akihiro Kimura, et al.
Case Reports in Dermatology|January 20, 2017
Bazex Syndrome in Lung Squamous Cell Carcinoma: High Expression of Epidermal Growth Factor Receptor in Lesional Keratinocytes with Th2 Immune ShiftMaki Amano, Takaaki Hanafusa, Sakiko Chikazawa, et al.
Current Medical Research and Opinion|December 3, 2024
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)Norito Katoh, Akio Tanaka, Hidetoshi Takahashi, et al.
Frontiers in Genetics|September 1, 2023
Clinical features and morphology of collagen fibrils in patients with vascular Ehlers-Danlos based on electron microscopySatoko Ishikawa, Shujiro Hayashi, Toshimi Sairenchi, et al.
Clinical Case Reports|October 22, 2020
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medicationYasutake Shinohara, Toshie Iijima, Shintaro Sakurai, et al.
The Journal of Investigative Dermatology|February 29, 2020
Anti-Inflammatory Effects of Potassium Iodide on SDS-Induced Murine Skin InflammationShujiro Hayashi, Satoko Ishikawa, Eisuke Ishii, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 24, 2025
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimabAndrew Blauvelt, Raj Chovatiya, Joseph F Merola, et al.
The British Journal of Dermatology|October 23, 2024
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)Norito Katoh, Akio Tanaka, Hidetoshi Takahashi, et al.
Acta Dermato-Venereologica|September 9, 2024
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic DermatitisAkio Tanaka, Ken Igawa, Hidetoshi Takahashi, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pageof 4